Abstract
ObjectiveTo compare the efficacy and safety of bioresorbable vascular stents (BVS) and drug-eluting stents (DES) in coronary heart disease.MethodsThe full text of clinical studies involving BVS and DES was retrieved in PubMed, Springer, EMBASE, Wiley-Blackwell, and Chinese Journal Full-text Database. Review Manager 5.3 was used for meta-analysis to evaluate the risk of target lesion failure, stent thrombosis and cardiac death in BVS and DES.ResultsFinally, 10 studies with 6383 patients were included in the meta-analysis. Compared with DES group, BVS group had significantly increased risk of target lesion failure (OR = 1.46, 95%CI 1.20–1.79, P = 0.0002; P Heterogeneity = 0.68, I2 = 0%), stent thrombosis (OR = 2.70, 95%CI 1.57–4.66, P = 0.0003; P Heterogeneity = 1.00, I2 = 0%) and cardiac death (OR = 2.19, 95%CI 1.17–4.07, P = 0.01; P Heterogeneity = 0.93, I2 = 0%).ConclusionThis study shows that DES is a safer treatment than BVS for coronary revascularization.
Highlights
Coronary heart disease (CHD), has been a leading cause of morbidity and mortality in the world [1, 2]
Two members of our team searched for articles independently using the following keywords: (1) bioresorbable stents OR bioresorbable vascular stents (BVS); (2) drug-eluting stents OR DES; Ni et al Journal of Cardiothoracic Surgery (2020) 15:26 (3) coronary heart disease OR CHD
The meta-analysis suggested that the target lesion failure of the BVS group was significantly higher than that of DES group with no heterogeneity among studies (OR = 1.46, 95% CI 1.20– 1.79, P = 0.0002; P Heterogeneity = 0.68, I2 = 0%; Fig. 2)
Summary
Coronary heart disease (CHD), has been a leading cause of morbidity and mortality in the world [1, 2]. The prevalence of CHD is increasing year by year and patients tend to be younger [3, 4]. Percutaneous coronary intervention (PCI) with stents is a common treatment strategy for CHD patients with significant stenosis of coronary arteries (> 70%). Drug-eluting stents (DES) are widely used in PCI. Compared with previous bare metal stents, the obvious improvement of DES is the carriers of anti-proliferation drugs [5]. The drug carriers of DES are mainly polymer coatings, which are designed to carry enough drug dosage and can effectively control the decomposition, diffusion and release of paclitaxel or other drugs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
